The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Top Research in Lupus Presented at ACR Convergence 2020

Top Research in Lupus Presented at ACR Convergence 2020

November 20, 2020 • By David S. Pisetsky, MD, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Abstract 0986—BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus

You Might Also Like
  • Dr. Blair Solow’s Picks for the Top RA Research Presented at ACR Convergence 2020
  • ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis
  • ACR Convergence 2020 Kicks Off: Plenary session speakers highlight racial differences in lupus & COVID-19-related findings
Also By This Author
  • Lessons from a Different Bench

Dr. Pisetsky: A striking feature of SLE is the so-called interferon signature, a pattern of gene expression of peripheral blood cells suggesting a powerful effect of type 1 interferon (IFN). Targeting IFN can be accomplished by direct binding of the cytokine, blockade of the IFN receptor or inhibition of cytokine production by plasmacytoid dendritic cells (PDCs), which are major producers of this cytokine. This study assessed the effects of a humanized monoclonal antibody (BIIB069) that binds to blood dendritic cell antigen 2 (BDCA2), a receptor uniquely expressed on PDCs. The data presented indicate that BIIB059 can reduce activity of cutaneous lupus erythematosus (CLE). Future studies will be needed to determine which of the strategies to reduce IFN activity is the most effective and, given the key role of PDCs in immune responses, the most safe.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Abstract 0988—Two-Year Results from a Randomized, Controlled Study of Obinutuzumab for Proliferative Lupus Nephritis

Dr. Pisetsky: In view of the abundant production of autoantibodies in SLE, B cells have long been considered an important target of therapy. Although belimumab (anti-BLyS/BAFF) was approved for the treatment of active, autoantibody positive SLE, clinical trials of the anti-CD20 monoclonal antibody rituximab (RTX) did not reach trial endpoints. This result has been surprising because elimination of B cells would seem an effective strategy to reduce the various roles that B cells can play in pathogenesis. One explanation for the failure of RTX in clinical trials is inadequate reduction of B cells. This study investigated the effects of a humanized type II anti-CD20 monoclonal antibody obinutuzumab (OBI) in lupus nephritis; OBI can produce more complete B cell depletion than RTX. As the data indicated, OBI treatment showed a higher frequency of complete renal responses than controls. These findings suggest that B cell depletion can be effective in the treatment of SLE, with the degree of depletion influencing outcomes.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Abstract 1828—Comprehensive Efficacy of Anifrolumab Across Organ Domains in Patients with Active SLE: Pooled Data from 2 Phase 3 Trials

Dr. Pisetsky: SLE is a clinically and serologically heterogeneous disease. This study assessed the effects of anifrolumab, a monoclonal antibody to the interferon receptor, on various organ domains in two phase 3 clinical trials. The results indicated efficacy for musculoskeletal and mucocutaneous manifestations, which were common in the trial populations. Interestingly, these studies assessed arthritis in terms of tender and swollen joint counts, suggesting that synovitis may be more prominent in SLE than sometimes thought.

Pages: 1 2 3 4 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Research Reviews, SLE (Lupus) Tagged With: ACR Convergence 2020, ACR Convergence 2020 - SLE, David S. Pisetsky, Lupus, Pisetsky

You Might Also Like:
  • Dr. Blair Solow’s Picks for the Top RA Research Presented at ACR Convergence 2020
  • ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis
  • ACR Convergence 2020 Kicks Off: Plenary session speakers highlight racial differences in lupus & COVID-19-related findings
  • New Lupus Classification Criteria Presented at ACR/ARHP Annual Meeting

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)